Oculis Advances Key Trials with June Data Readout on Horizon

Event summary

  • Completed last patient last visit (LPLV) in DIAMOND Phase 3 trials for OCS-01, with topline data expected in June 2026.
  • Licaminlimab PREDICT-1 trial in active recruitment phase for dry eye disease, targeting year-end results.
  • Privosegtor cleared by FDA SPA for PIONEER-1 Phase 3 trial, with ongoing site activation.
  • Cash position of $277.6 million as of March 31, 2026, providing runway into 2H 2029.

The big picture

Oculis is positioning itself at the forefront of neuro-ophthalmology and ophthalmology innovation, targeting a combined market opportunity exceeding $30 billion. The company's strategic focus on non-invasive treatments and precision medicine aligns with broader industry trends toward personalized healthcare solutions. The upcoming data readouts and regulatory milestones will be critical in determining the company's trajectory in a competitive therapeutic landscape.

What we're watching

Regulatory Milestones
Whether the FDA and EMA approvals will accelerate Privosegtor's market entry.
Clinical Trial Outcomes
The impact of OCS-01's June data readout on diabetic macular edema treatment paradigms.
Precision Medicine
How Licaminlimab's genotype-driven approach will reshape dry eye disease management.